Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Receivables - Other (2018 - 2022)

Ani Pharmaceuticals' Receivables - Other history spans 5 years, with the latest figure at $5.0 million for Q4 2022.

  • For Q4 2022, Receivables - Other changed N/A year-over-year to $5.0 million; the TTM value through Dec 2022 reached $5.0 million, changed N/A, while the annual FY2022 figure was $5.0 million, N/A changed from the prior year.
  • Receivables - Other for Q4 2022 was $5.0 million at Ani Pharmaceuticals, up from $100000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $5.0 million in Q4 2022 and bottomed at $14000.0 in Q3 2018.
  • The 4-year median for Receivables - Other is $100000.0 (2018), against an average of $581400.0.
  • The largest YoY upside for Receivables - Other was 614.29% in 2019 against a maximum downside of 0.0% in 2019.
  • A 4-year view of Receivables - Other shows it stood at $100000.0 in 2018, then changed by 0.0% to $100000.0 in 2019, then changed by 0.0% to $100000.0 in 2020, then soared by 4900.0% to $5.0 million in 2022.
  • Per Business Quant, the three most recent readings for ANIP's Receivables - Other are $5.0 million (Q4 2022), $100000.0 (Q3 2020), and $100000.0 (Q2 2020).